Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company focused on rare neuroendocrine diseases, announced significant changes to its Board of Directors on April 1, 2026. The company has appointed Kimberly J. Popovits as a non-employee director, effective immediately. Popovits, who has over 40 years of experience in the life sciences sector, will serve as a Class II director until the 2028 annual meeting of stockholders. Her extensive background includes leadership roles at Genomic Health and Genentech, where she was instrumental in the commercialization of innovative therapies.

In conjunction with this appointment, Edward T. Mathers has resigned from the Board, also effective April 1, 2026. The company stated that Mathers' resignation was not due to any disagreements regarding the company's operations or policies. David Meeker, M.D., Chairman and CEO of Rhythm, expressed gratitude for Mathers' contributions over the years, highlighting his strategic perspective and leadership.

The changes were formally disclosed in a press release on April 3, 2026, which is available as an exhibit in the company's 8-K filing. The company anticipates that Popovits' expertise will be invaluable as Rhythm continues to advance its mission and growth strategy in the biopharmaceutical landscape. This leadership change is expected to have a positive impact on the company's strategic direction and operational execution, aligning with its goals to innovate and provide solutions for patients with rare diseases.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.